11 credit hours (CME) have been awarded to the Symposium 207 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology.
Preface

In recent years medicine has witnessed an astonishing paradigm shift. For decades it was believed that for most diseases the individual risk was defined by the genetic make-up, potentially modified by the environment and lifestyle-factors. It has now emerged that the gut microbiome plays an equally important role for many gastrointestinal and non-gastrointestinal disorders. This opens astonishing new avenues to understand and target disease mechanisms in particular in relation to immune mediated diseases but might be equally important for the prevention of disease. Thus the organisers Gerald Holtmann and Mark Morrison from Brisbane, Nicholas Talley from Newcastle, William Chey from Ann Arbor, and Peter Gibson from Melbourne in close collaboration with other experts in the field have developed a scientific program that brings together basic scientists and clinicians from many disciplines to define our current knowledge and define future directions that are relevant for the translation of this knowledge into clinical practice.

On behalf of the scientific committee

Prof. Gerald Holtmann, Brisbane
Gut Microbiome and Mucosal or Systemic Dysfunction: Mechanisms, Clinical Manifestations and Interventions

May 19 – 20, 2017
Brisbane Convention & Exhibition Centre
Brisbane, Australia

Registration:
Thursday, May 18, 2017
16.00 – 21.00 h
at the congress office

Congress Venue:
Brisbane Convention & Exhibition Centre
Merivale St & Glenelg Street
South Brisbane, QLD 4101
Australia

The Symposium 207 is organized by Falk Foundation e.V.

Scientific Organization:
Prof. Gerald Holtmann
Princess Alexandra Hospital
University of Queensland
199 Ipswich Road
Brisbane, QLD 4102, Australia
Telephone: +617 31 76 77 92
Telefax: +617 31 76 51 11
E-Mail: g.holtmann@uq.edu.au

Scientific Co-Organization:
W.D. Chey, Ann Arbor (USA)
P.R. Gibson, Melbourne (Australia)
M. Morrison, Brisbane (Australia)
M. Simrén, Gothenburg (Sweden)
N.J. Talley, Newcastle (Australia)

Official Language:
English

Posters:
A poster session will take place.
For details see page 12.
Friday, May 19, 2017

8.30 Welcome
G. Holtmann, Brisbane

8.40 Associate Director General, Department of Science, Information Technology and Innovation
C. Williams, Brisbane

Session I
The fundamentals and how to determine what really matters
Chair: H.M. Mitchell, Sydney; G. Tyson, Brisbane

8.50 State-of-the-Art Lecture:
Prevalent but uncharacterised microbial populations in the human gut microbiome
P. Hugenholtz, Brisbane

9.25 Crosstalk between microbiota, pathogens and the innate immune responses
J. Wehkamp, Tübingen

9.45 Morphology of inflammatory changes of the mucosa: Time to reassess inflammatory responses of the mucosa
M.M. Walker, Newcastle

10.05 Making it all fit – Statistical challenges and new data analysis methods for integrating microbiome data with other clinical measures
K.-A. Le Cao, Brisbane

10.25 Assessment of symptoms in FGID and IBD studies that target the GI microbiome
M.P. Jones, Sydney

10.45 Coffee break with poster session

Session II
Microbiome-host interactions
Chair: M. Morrison, Brisbane; C. O’Brien, Canberra

11.15 State-of-the-Art Lecture:
Faecalibacterium prausnitzii and other next-generation probiotics to prevent and to treat gastrointestinal disorders and diseases in humans
P. Langella, Jouy-en-Josas

11.45 Does host genotype shape the gut microbiome?
M.-E. Costello, Brisbane

12.05 How does the gut microbiota affect the epigenome?
M.V. Joglekar, Sydney
Friday, May 19, 2017

12.25 A question of culture? Development and differentiation of the mucosal and luminal microbiomes  
P. O Cuiv, Brisbane

12.45 The role of mucins in shaping the microbiome?  
M. McGuckin, Brisbane

13.05 How does epithelial cell stress affect the nutrient and physical landscapes of the microbiome?  
S. Keely, Newcastle

13.25 Oral poster presentation:  
The induction of dysbiosis in the small intestine promotes allergic sensitisation  
G. Burns, Newcastle

13.35 Oral poster presentation:  
Faecal supernatants from patients with diarrhoea predominant IBS disrupt colonic epithelial barrier function and directly affect colorectal afferent nerves  
H. Wardill, Adelaide

13.45 Lunch with poster session

Session III
The gastrointestinal microbiome, diet and management of chronic diseases

Chair: E. Powell, Brisbane; S. Roberts, Melbourne

14.45 Microbes affecting gastrointestinal growth and function: Role of the aryl-hydrocarbon-receptor  
S. Pettersson, Singapore

15.05 Effect of eradication therapy of H. pylori on gut microbiota  
K. Sugano, Tochigi

15.25 Pre-, pro- and synbiotics for chronic kidney disease  
K. Campbell, Brisbane

15.45 The microbiome and obesity: Cause, consequence or both?  
A. Holmes, Sydney

16.05 Oral poster presentation:  
Reducing the maternal dietary intake of indigestible and slowly absorbed short-chain carbohydrates is associated with improved infantile colic: A proof-of-concept study  
M. Iacovou, Melbourne

16.15 Oral poster presentation:  
The prebiotic impact of dietary FODMAPs on intestinal microbiota  
E.P. Halmos, Melbourne

16.25 Coffee break with poster session
Friday, May 19, 2017

Session IV
Intended and unintended alterations of the human microbiome

Chair: J. Gapasin-Tongo, Quezon City; M. Grimm, Sydney

16.45 State-of-the-Art Lecture:  
Comparative efficacy of traditional treatments and treatments targeting the microbiome in IBD and IBS

P. Moayyedi, Hamilton

17.15 The FODMAP diet - A microbiome targeted intervention and what could be the consequences?  
M. Chen, Guangzhou

17.35 Debate: Faecal microbiota transplantation:  
Are we ready for prime-time?

Chair: W.D. Chey, Ann Arbor

PRO: Faecal microbiota transplantation (FMT) – Ready for prime time

M.A. Kamm, Melbourne

CONTRA

J. Andrews, Adelaide

17.55 Summary of the day

E.M. El-Omar, Sydney

18.05 Scientific discussion with snacks
Saturday, May 20, 2017

Session V
The gastrointestinal microbiome and extraintestinal diseases

Chair: G. Hebbard, Melbourne; B. Kendall, Brisbane

8.30 State-of-the-Art Lecture: E.A. Mayer, Los Angeles
Microbiome and brain function in health and disease

9.00 Anxiety and depressive disorders, the inflammasome, and the gut microbiome M. Gray, Brisbane

9.20 Distinct oral and fecal community profiles enriched in opportunistic pathogens in rheumatoid arthritis patients R. Thomas, Brisbane

9.40 Friend or foe: The microbiome in liver disease L. Adams, Perth

10.00 Oral poster presentation: A. Loughman, Melbourne
Gut microbiota composition and behaviour problems in early childhood

10.10 Oral poster presentation: L. Bajer, Prague
Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis

10.20 Coffee break with poster session

Session VI
Targeting the mucosal microbiome and mucosal immune responses

Chair: T. Florin, Brisbane; R.W.L. Leong, Sydney

10.50 State-of-the-Art Lecture: H. Ohno, Yokohama
The function of M cells in host-microbe interactions

11.20 The mucosal microbiome of the upper GI tract and its role in FGIDs E.R. Shanahan, Brisbane

11.40 The gut-lung axes and IBD K.M. Fock, Singapore

12.00 The microbiome, autophagy and IBD J. Begun, Brisbane
Saturday, May 20, 2017

12.20 Characterising local and systemic immune response in functional dyspepsia  
A. Do, Brisbane

12.40 **Oral poster presentation:**  
Esophageal dysbiosis in Barrett’s esophagus and esophageal adenocarcinoma  
T.-M.-T. Nguyen, Brisbane

12.50 **Oral poster presentation:**  
Reduced abundance of Faecalibacterium prausnitzii in the terminal ileum mucosa-associated microbiome correlates with increased small intestinal permeability in chronic liver disease  
A.S. Raj, Brisbane

13.00 **Presentation of poster awards**  
P.R. Gibson, Melbourne

13.15 Lunch break with poster session

**Session VII**
What are the challenges and opportunities of future approaches to maintain or improve health and wellbeing by targeting the microbiome?

*Chair:* K.M. Fock, Singapore; R. Ward, Brisbane

14.10 **State-of-the-Art Lecture:**  
The current and future assessment and targeted modulation of the gastrointestinal microbiome in the clinical setting  
E.M.M. Quigley, Houston

14.40 The host genes and associations with the microbiome: Implications for targeted interventions  
S.C. Ng, Hong Kong

15.00 Diets, functional foods, such as EEN or PEN and inflammatory bowel disease  
P. Lewindon, Brisbane

15.20 Coffee break with poster session

15.50 Next generation microbiology: Monitoring the resistome by shot gun metagenomics to fight the spread of antimicrobial resistance  
I. Autenrieth, Tübingen

16.10 The clinician’s perspective of needs and opportunities in developing countries  
U.C. Ghoshal, Lucknow
Saturday, May 20, 2017

16.30 Oral poster presentation:  
A type 1 diabetes associated core microbiome driven by interleukin 2 pathway and MHC genetic variation  
J.A. Mullaney, Brisbane

16.40 Oral poster presentation:  
Postoperative Crohn’s disease recurrence is associated with specific changes in the faecal microbiome – Potential pathogenic and protective roles  
A.L. Hamilton, Melbourne

16.50 Summary & conclusions  
G. Holtmann, Brisbane  
N.J. Talley, Newcastle  
M. Morrison, Brisbane
Poster Session

Posters will be exhibited on May 19 and May 20, 2017 in the Brisbane Convention & Exhibition Centre. The authors will be in attendance during coffee and lunch breaks on both days.

1. Intestinal dysbiosis in patients with short bowel syndrome dependent on total parenteral nutrition is reflected by altered metabolome in faeces
   L. Bajer, M. Kostovcik, J. Hradecky, T. David, P. Wohl, J. Spicak, P. Drastich, M. Cahova (Prague, CZ)

2. District gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis

3. Effect of native and acetylated high amylose maize starch on fecal pH, short chain fatty acid concentrations and fecal microbiota in a cohort of non-stunted and stunted children in southern India
   R. Balamurugan, S. Pugazhendi, B.M. Gowri, D. Tamilselvan, E. Mortimer, G. Gopalsamy, R.J. Woodman, R. Meng, M. Manary, H.J. Binder, I. Brown, G.P. Young, B.S. Ramakrishna (Vellore, IN; Adelaide, AU; St. Louis, New Haven, US)

4. Organic alternative to in feed antibiotics in agriculture
   B.W. Bauer, J.R. McIntyre, K.B. Walsh, R.J. Moore, D. Stanley (Rockhampton, Melbourne, AU)

5. Antibiotic treatment reduces oral and colonic expression of sweet taste receptor TAS1R2

6. Stress-mediated activation of NLRP6 drives immune dysfunction in functional gastrointestinal disorders (FGIDs)

7. Regulation of lung macrophage metabolism and gene expression via the gut-microbiota-lung axis and SCFAs protects against cigarette smoke-induced lung pathology
   K.F. Budden, S.L. Gellatly, D.L.A. Wood, M. Morrison, M.A. Cooper, P. Dennis, P. Hugenholtz, P.M. Hansbro (Newcastle, Brisbane, AU)

8. Probiotics, the gut microbiome and depression: A clinical trial to assess the effect of probiotics on depression
   C. Burke, S. van Hemert, S. Kwan, L. Roberts (Sydney, AU; Amsterdam, NL)

9. Functional and genomic analyses of the Faecalibacterium prausnitzii Mam protein
   S. Burman, J.M. Chatel, J. Daly, G. Tyson, P. Langella, P. O Cuiv, M. Morrison (Brisbane, AU; Jouy-en-Josas, FR)

10. The induction of dysbiosis in the small intestine promotes allergic sensitisation
11. Statin therapy causes microbiome alteration and gut dysbiosis in mice
   J.A. Caparros-Martin, R.R. Lareu, J. Ramsay, J. Peplies, F.J. Reen, P. Newsholme,
   J. Hughes, F. O’Gara (Perth, AU; Bremen, DE; Cork, IE)

12. Oral delivery of pancreatitis-associated protein (PAP) by Lactococcus lactis
displays protective effects in mouse acute colitis model through Treg induction
   J.-M. Chatel, N. Breyner, R.D. da Carvalho, T. Rochat, P. Bagano, V. Boas,
   D. Pontes, F. Chain, H. Sokol, M. Azevedo, A. Myioshi, V.A. Azevedo, P. Langella,
   L.G. Bermudez-Humaran (Jouy-en-Josas, FR; Belo Horizonte, BR)

13. A proposal for a randomized study of allogeneic vs. autologous fecal microbiome
    transplant (FTM) in patients with non-alcoholic steatohepatitis (NASH)

14. Iron supplementation does not alter the gut microbiome in early pregnancy
    M. Dekker Nitert, L.F. Gomez-Arango, D.M. Frazer, H. Barrett, L.K. Callaway,
    G.J. Anderson (Brisbane, AU)

15. Iron deficiency anaemia: Effects on small intestine T-lymphocyte and immune
    function
    A. Do, Y. Li, A. Shah, P. Ghasemi, E. Shanahan, T. Hansen, N. Koloski, N.J. Talley,
    G. Holtmann (Brisbane, Newcastle, AU)

16. Alterations of T-lymphocyte subpopulations in association with bowel symptoms
    in functional dyspepsia and functional dyspepsia-irritable bowel syndrome overlap
    G. Holtmann (Brisbane, Newcastle, AU)

17. Early manipulation of intestinal microbiota
    E. Donaldson, J. McIntyre, S. Baldwin, R. Hughes, R. Moore, D. Stanley
    (Rockhampton, Roseworthy, Melbourne, AU)

18. Influence of selenium nanoparticles on intestinal health and Faecalibacterium
    prausnitzii abundance
    S. Gangadoo, J. Chapman, R.J. Hughes, T.T.H. Van, R.J. Moore, D. Stanley
    (Rockhampton, Roseworthy, Melbourne, AU)

19. Metaproteomics: Predicting risk of developing type 1 diabetes
    P. Gavin, J. Mullaney, D. Zipris, E.E. Hamilton-Williams (Brisbane, AU; Denver, US)

20. Role of anti-inflammatory gut bioactivates in the modulation of immune
    response in Crohn’s disease
    R. Giri, P. O Cuiv, J. Begun (Brisbane, AU)

21. Hypoxia inducible factor (HIF)-1 accelerates epithelial wound healing through
    integrin regulation
    B.J. Goggins, K. Minahan, N. Outteridge, D. Knight, J. Horvat, S. Keely (New-
    castle, AU)

22. A fibre-deprived diet influences Collinsella abundance in the overweight and
    obese pregnant microbiome and alters maternal metabolic risk
    L.F. Gomez-Arango, H.L. Barrett, S. Wilkinson, L.K. Callaway, H.D. McIntyre,
    M. Morrison, M. Dekker Nitert (Brisbane, AU)
23. Resistant starch as a novel prebiotic in infants

24. Reduced GI symptoms and premotor cortex activation in Crohn’s disease following anti-TNFα treatment
M. Gray, C. Chao, N.J. Talley, N. Koloski, G. Holtmann (Brisbane, Newcastle, AU)

25. Anti-TNFα treatment in Crohn’s disease reduces GI symptoms and alters neuro-circuitry underlying motivation
M. Gray, C. Chao, N.J. Talley, N. Koloski, G. Holtmann (Brisbane, Newcastle, AU)

26. Anti-TNFα in IBD improves positive attribution bias and gastrointestinal symptoms
M. Gray, C. Chao, N.J. Talley, N. Koloski, G. Holtmann (Brisbane, Newcastle, AU)

27. The prebiotic impact of dietary FODMAPs on intestinal microbiota

28. Postoperative Crohn’s disease recurrence is associated with specific changes in the faecal microbiome – Potential pathogenic and protective roles

29. Intrafamilial spread of Helicobacter pylori infection in North Jakarta

30. Acquired and innate immune responses are inhibited in IBS-D in symptom flare vs. symptom free
P. Hughes, C. Mavrangelos, M. Campanello, P. Bampton, J. Andrews (Adelaide, AU)

31. Reducing the maternal dietary intake of indigestible and slowly absorbed short-chain carbohydrates is associated with improved infantile colic: A proof-of-concept study
M. Iacovou, E.C. Mulcahy, H. Truby, J.S. Barrett, P.R. Gibson, J.G. Muir (Melbourne, AU)

32. Post OP Crohn’s disease maintenance: Is AZA a better option – An Indian study
B.P.N. Kaushik, D. Kshaunish, S. Rajib, D. Gopal Krishna (Kolkata, IN)

33. The role of small intestinal bacterial overgrowth in pathogenesis of lactase deficiency
O. Knyazev, N. Fadeeva, I. Ruchkina, A.I. Parfenov, P. Shcherbakov (Moscow, RU)

34. Antibiotic resistance genes in the gut microbiome of pregnant women

35. Fecal microbiota transplantation: Should we form European cooperative network?
P. Kohout, J. Vejmelka (Prague, CZ)
36. Responses of circulating granulocytes in functional dyspepsia patients
Y. Li, A. Do, E. Shanahan, N. Koloski, T. Hansen, A. Shah, S. Keely, N.J. Talley,
G. Holtmann (Guangzhou, CN; Brisbane, Newcastle, AU)

37. Keeping your MAITs in line; interrogating MAIT cell activation in an animal
model of inflammatory bowel disease
R.-J. Lohman, J.Y.W. Mak, L. Liu, A. Do, D. Fairlie (Brisbane, AU)

38. Gut microbiota composition and behaviour problems in early childhood
A. Loughman, M. O’Hely, F. Collier, M. Conlon, C. Symeonides, A.-L. Ponsonby,
P. Vuillermin; Barwon Infant Study Investigator Group (Melbourne, Geelong,
Adelaide, AU)

39. Platelet-activating factor signalling drives pulmonary inflammation in animal
models of colitis
A. Mathe, S. Mateer, J. Bruce, P. Foster, J. Horvat, P.M. Hansbro, S. Keely
(Newcastle, AU)

40. Microbial colonisation of the duodenal-jejunal bypass sleeve used for treatment
of obesity: Results of a pilot study
J. McMaster, E. Shanahan, G. Rich, V. Chachay, M. Morrison, G. Holtmann
(Brisbane, AU)

41. Alteration of the microbiome effects neuroprotective mechanisms in an animal
model of glaucoma
Z.E. McPherson, M. McEvoy, H.U. Lee, N.J. Talley, A. Agar, M. Coroneo,
S. Pettersson (Newcastle, Sydney, AU; Singapore, SG; Stockholm, SE)

42. Hierarchical structure of mucin within the gastrointestinal tract and its interaction
with dietary components
O. Meldrum, G.E. Yakubov, M.A. McGuckin, M.J. Gidley (Brisbane, AU)

43. A type 1 diabetes associated core microbiome driven by interleukin 2 pathway
and MHC genetic variation
J.A. Mullaney, J.E. Stephens, C. Fong, B.E. Geeling, E.E. Hamilton-Williams
(Brisbane, AU)

44. Fecal transplant special way: The results of jejunal delivery in our practice
B. Nagy, Z. Csapo (Kistarcsa, HU)

45. Esophageal dysbiosis in Barrett’s esophagus and esophageal adenocarcinoma
T.M.T. Nguyen, E. Shanahan, L. Krause, D.C. Whiteman, B.J. Kendall,
L.F. Hourigan, A.P. Barbour, G. Holtmann, M. Morrison, M. Hill (Brisbane, AU)

46. Tight junction dysfunction not present in a chronic fatigue syndrome/myalgic
encephalomyelitis cohort
Coast, AU)

47. Clostridium difficile isolation and characterization from hospitalized patients –
A pilot study from gastroenterological ward of a tertiary institution
S. Pintar, M. Rupnik, P. Skok (Maribor, SI)
48. Mucosal washings, a new technique for sampling the mucosal microbiota community
   C. Poulton, A. Lemberg, A. Day, E. Wine, S. Leach (Sydney, AU)

49. Reduced abundance of Faecalibacterium prausnitzii in the terminal ileum mucosa-associated microbiome correlates with increased small intestinal permeability in chronic liver disease

50. Treatment of ZAP-70 mutant SKG mice with anti-IL-23 antibody alters fecal microbiota composition and prevents outgrowth of bacteria associated with susceptibility to spondyloarthritis and ileitis
   L.M. Rehaume, N. Matigian, K. Ormerod, A. Kang, R. Linedale, O. Zbarskaya, K. Kikly, J. Daly, N. Lachner, P. Hugenholtz, M. Morrison, K.-A. Le Cao, R. Thomas (Brisbane, AU; Indianapolis, US)

51. A novel approach to quantify small intestinal bacterial load: A pilot study in Crohn’s disease, functional gastrointestinal disorders and patients with iron deficiency

52. Is there a link between H. pylori and the epidemiology of Crohn’s disease

53. Is there an association between enteric methane (CH4) production and symptoms in patients with unexplained GI symptoms?
   A. Shah, L. Fletcher, P. Ghasemi, T. Hansen, M. Morrison, G. Holtmann (Brisbane, AU)

54. Systematic review and meta-analysis: Prevalence of small intestinal bacterial overgrowth in chronic liver disease
   A. Shah, E. Shanahan, G. Macdonald, L. Fletcher, M. Morrison, A. Raj, M. Jones, G. Holtmann (Brisbane, Sydney, AU)

55. Life in the duodenum: Isolation of small intestinal mucosa-associated bacteria in functional dyspepsia patients
   E. Shanahan, A. Do, A. Sheela Nair, A. Rameshkumar, P. O Cuiv, M. Morrison, G. Holtmann (Brisbane, AU)

56. The effect of dietary fibre on gut microbiota composition in healthy adults: A systematic review and meta-analysis
   D. So, K. Whelan, M. Rossi, M. Morrison, H. Staudacher, K. Campbell (Gold Coast, Brisbane, AU; London, GB)

57. Stroke induces robust changes to intestinal mucosal microbiota
   D. Stanley, R.J. Moore, C.H.Y. Wong (Rockhampton, Melbourne, AU)

58. High rates of Clostridium difficile infection in inflammatory bowel disease admissions to a tertiary referral centre
   K.M. Taylor, B.J. Headon, R.P. Luber, M.P. Sparrow (Melbourne, AU)
59. Oral α-galactosidase improves gastrointestinal tolerance to a diet high in galacto-oligosaccharides: Adjunct therapy to a low FODMAP diet in irritable bowel syndrome
C.J. Tuck, K.M. Taylor, J.S. Barrett, P. R. Gibson, J. Muir (Melbourne, AU)

60. Faecal supernatants from patients with diarrhoea predominant IBS disrupt colonic epithelial barrier function and directly affect colorectal afferent nerves

61. Translocation and dissemination of commensal bacteria in post-stroke infection
C.H.Y. Wong, D. Stanley, L.J. Mason, K.E. Mackin, Y.N. Srikhanta, D. Lyras, M.D. Prakash, K. Nurgali, A. Venegas, M.D. Hill, R.J. Moore (Melbourne, Rockhampton, AU; Calgary, CA)

List of Speakers, Moderators and Scientific Organizers

Assoc. Prof. Leon Adams
School of Medicine and Pharmacology
University of Western Australia
Verdun Street
Nedlands, WA 6009
Australia
leon.adams@uwa.edu.au

Prof. Jane Andrews
Dept. of Gastroenterology & Hepatology
Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000
Australia
jane.andrews@sa.gov.au

Prof. Ingo Autenrieth
Medizinische Mikrobiologie
Universitätsklinikum Tübingen
Elfriede-Aulhorn-Str. 6
72076 Tübingen
Germany
ingo.autenrieth@med.uni-tuebingen.de

Dr. Lukas Bajer
Hepatogastroenterology
IKEM Prague
Videnska 9
140 21 Praha 4
Czech Republic
lukasbajer1@gmail.com

Dr. Jakob Begun
Mater Research Institute
University of Queensland
Aubigny Bldg., Level 3
Raymond Terrace
South Brisbane, QLD 4101
Australia
jakob.begun@mater.uq.edu.au

Grace Burns
HMRI Bldg.
University of Newcastle
Lot 1 Kookaburra Close
New Lambton Heights, NSW 2305
Australia
g.burns@newcastle.edu.au

Dr. Katrina Campbell
Nutrition and Dietetics
Princess Alexandra Hospital
199 Ipswich Rd,
Woolloongabba, QLD 4102
Australia
katrina.campbell@health.qld.gov.au

Prof. Minhu Chen
Dept. of Gastroenterology and Hepatology
The First Affiliated Hospital
Sun Yat-sen University 58 Zhongshan Road II
510080 Guangzhou
China
chenminhu@vip.163.com

William D. Chey, M.D.
Professor of Internal Medicine
Division of Gastroenterology
University of Michigan
3912 Taubman Center, SPC 5362
Ann Arbor, MI 48109
USA
wchey@med.umich.edu

Dr. Mary-Ellen Costello
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Institute
37 Kent Street
Woolloongabba, QLD 4102
Australia
m.costello@qut.edu.au

Dr. Anh Do
PAH, Dept. of Gastroenterology & Hepatology
Translational Research Institute
University of Queensland
37 Kent Street
Woolloongabba, QLD 4102
Australia
a.do@uq.edu.au
Prof. Gerald Holtmann
Princess Alexandra Hospital
University of Queensland
199 Ipswich Road
Brisbane, QLD 4102
Australia
g.holtmann@uq.edu.au

Dr. Philip Hugenholtz
School of Chemistry & Molecular Biosciences
Australian Centre for Ecogenomics
University of Queensland
St Lucia, QLD 4072
Australia
p.hugenholtz@uq.edu.au

Marina Iacovou
Department of Gastroenterology
Monash University - FODMAP Initiative
The Alfred Centre
Level 6, 99 Commercial Road
Melbourne, VIC 3004
Australia
marina.iacovou@monash.edu

Dr. Mugdha V. Joglekar
Diabetes and Islet Biology
NHMRC Clinical Trials Centre
Faculty of Medicine
University of Sydney
Level 1, Medical Foundation Bldg.
92-94 Parramatta Road,
Camperdown, NSW 2050
Australia
mugdha.joglekar@ctc.usyd.edu.au

Prof. Michael P. Jones
Psychology Department
Faculty of Human Sciences
Macquarie University
North Ryde, NSW 2109
Australia
mike.jones@mq.edu.au

Prof. Michael A. Kamm
Department of Gastroenterology
St. University Dept. of Medicine
Vincent’s Hospital
Victoria Parade
Melbourne, VIC 3065
Australia
mkamm@unimelb.edu.au

Dr. Simon Keely
Faculty of Health and Medicine
School of Biomedical Sciences and Pharmacy
University of Newcastle
University Drive
Callaghan, NSW 2308
Australia
simon.keely@newcastle.edu.au

Dr. Bradley Kendall
Dept. of Gastroenterology and Hepatology
Princess Alexandra Hospital
199 Ipswich Road
Brisbane, QLD 4102
Australia
bradley.kendall@health.qld.gov.au

Dr. Philippe Langella
Micalis Institute
Laboratory of Commensals and Probiotics-Host Interactions
Allée de Vilvert
78352 Jouy-en-Josas
France
philippe@langella@jouy.inra.fr

Dr. Kim-Anh Le Cao
Translational Research Institute
University of Queensland
37 Kent Street
Woollahra, QLD 4102
Australia
k.lecao@uq.edu.au

Prof. Rupert W.L. Leong
Gastroenterology and Liver Services
Concord Hospital
University of Sydney
Sydney, NSW 2139
Australia
rupert.leong@sswhhs.nsw.gov.au
Assoc. Prof. Peter Lewindon  
Dept. of Gastroenterology  
Lady Cilento Children’s Hospital  
501 Stanley Street  
Brisbane, QLD 4101  
Australia  
peter.lewindon@health.qld.gov.au

Amy Loughman  
RMIT University  
PO Box 71  
Bundoora, VIC 3083  
Australia  
amy.loughman@rmit.edu.au

Emeran A. Mayer, M.D.  
Dept. of Gastroenterology  
Ronald Reagan UCLA Medical Center  
757 Westwood Plaza  
Los Angeles, CA 90095  
USA  
emayer@ucla.edu

Prof. Michael McGuckin  
Mater Research Institute  
Translational Research Institute  
University of Queensland  
37 Kent Street  
Woolloongabba, QLD 4102  
Australia  
michael.mcguckin@mater.uq.edu.au

Prof. Hazel M. Mitchell  
School of Biotechnology and Biomolecular Sciences  
University of New South Wales  
Sydney, NSW 2052  
Australia  
h.mitchell@unsw.edu.au

Prof. Paul Moayyedi  
Division of Gastroenterology  
McMaster University  
1280 Main St. W.  
HSC-3V3  
Hamilton, ON L8S 4K1  
Canada  
moayyep@mcmaster.ca

Prof. Mark Morrison  
Translational Research Institute  
University of Queensland Diamantina Inst.  
37 Kent Street  
Woolloongabba, QLD 4102  
Australia  
m.morrison1@uq.edu.au

Dr. Jane A. Mullaney  
Translational Research Institute  
University of Queensland  
37 Kent Street  
Woolloongabba, QLD 4102  
Australia  
j.mullaney@uq.edu.au

Prof. Siew C. Ng  
Dept. of Medicine and Therapeutics  
Institute of Digestive Diseases  
Chinese University Hong Kong  	Ngan Shing Street, Shatin, NT  
Hong Kong  
siewchienng@cuhk.edu.hk

Thi-My-Tam Nguyen  
Translational Research Institute  
University of Queensland  
37 Kent Street  
Woolloongabba, QLD 4102  
Australia  
t.nguyen6@uq.edu.au

Dr. Claire O’Brien  
ANU College of Medicine, Biology and Environment  
Australian National University  
Florey Building  
54 Mills Rd.  
Acton, ACT 2601  
Australia  
claire.obrien@anu.edu.au

Dr. Paraic O Cuiv  
Translational Research  
University of Queensland Diamantina Inst.  
37 Kent Street  
Woolloongabba, QLD 4102  
Australia  
p.ocuiv@uq.edu.au
Dr. Hiroshi Ohno  
Laboratory for Intestinal Ecosystem  
RIKEN Center for Integrative Medical Sciences (IMS)  
1-7-22 Suehiro  
Tsurumi, Yokohama 230-0045  
Japan  
hiroshi.ohno@riken.jp

Prof. Sven Pettersson  
Lee Kong Chian School of Medicine  
Nanyang Technological University  
50 Nanyang Avenue  
Singapore 639798  
Singapore  
sven.pettersson@ki.se

Prof. Elizabeth Powell  
Princess Alexandra Hospital  
199 Ipswich Rd.  
Woolloongabba, QLD 4102  
Australia  
e.powell@uq.edu.au

Eamonn M.M. Quigley, M.D.  
Professor of Medicine  
Gastroenterology and Hepatology  
The Methodist Hospital  
6565 Fannin Street  
Houston, TX 77030  
USA  
equigley@houstonmethodist.org

Dr. Ashok S. Raj  
School of Medicine  
University of Queensland  
5/36 Kitchener Street  
Coorparoo, QLD 4151  
Australia  
monkeyraj@gmail.com

Prof. Stuart Roberts  
Dept. of Gastroenterology and Hepatology  
The Alfred Centre  
99 Commercial Rd,  
Melbourne, VIC 3004  
Australia  
s.roberts@alfred.org.au

Prof. Magnus Simrén  
Dept. of Internal Medicine & Clinical Nutrition  
Institute of Medicine  
Sahlgrenska Academy  
413 45 Gothenburg  
Sweden  
magnus.simren@medicine.gu.se

Dr. Erin R. Shanahan  
Dept. of Gastroenterology and Hepatology  
Princess Alexandra Hospital  
University of Queensland  
37 Kent Street  
Woolloongabba, QLD 4102  
Australia  
e.shanahan@uq.edu.au

Prof. Kentaro Sugano  
Department of Medicine  
Division of Gastroenterology  
Jichi Medical University  
3311-1 Yakushiji, Shimotsuke  
Tochigi 329-0498  
Japan  
sugano@jichi.ac.jp

Prof. Nicholas J. Talley  
Faculty of Health and Medicine  
University of Newcastle  
University Drive  
Callaghan, NSW 2308  
Australia  
nicholas.talley@newcastle.edu.au

Prof. Ranjeny Thomas  
Translational Research Institute  
University of Queensland Diamantina Inst.  
37 Kent Street  
Woolloongabba, QLD 4102  
Australia  
ranjeny.thomas@uq.edu.au

Prof. Gene Tyson  
Australian Centre for Ecogenomics  
Level 5, Molecular Biosciences Bldg.  
University of Queensland  
St Lucia, QLD 4072  
Australia  
g.tyson@uq.edu.au
Prof. Marjorie M. Walker  
Anatomical Pathology  
School of Medicine and Public Health  
Faculty of Health and Medicine  
University of Newcastle  
University Drive  
Callaghan, NSW 2308  
Australia  
marjorie.walker@newcastle.edu.au

Dr. Hannah Wardill  
Centre for Nutrition and Gastrointestinal Disease  
University of Adelaide  
North Terrace Campus  
Adelaide, SA 5005  
Australia  
hannah.wardill@adelaide.edu.au

Prof. Robyn Ward  
Faculty of Medicine  
Biomedical Sciences  
University of Queensland  
UQ Oral Health Centre,  
Building 883, Herston Rd,  
Herston, QLD 4006  
Australia  
mbs.execdean@uq.edu.au

Prof. Jan Wehkamp  
Innere Medizin I  
Universitätsklinikum Tübingen  
Otfried-Müller-Str. 10  
72076 Tübingen  
Germany  
jan.wehkamp@med.uni-tuebingen.de
Congress Office

During the Symposium in Brisbane

Congress Office Telephone: +49 (0)175/7795327

Opening Hours:
Thursday, May 18, 2017  16.00 – 21.00 h
Friday, May 19, 2017    7.00 – 18.00 h
Saturday, May 20, 2017  8.00 – 17.00 h

Brisbane Convention &
Exhibition Centre
Merivale St & Glenelg Street
South Brisbane, QLD 4101
Australia

Admission to Scientific Program
For admission to scientific program your name badge should be clearly visible.

Airport
(approx. 18 km from the congress venue)